Have any questions? 706-721-6582 or cts@augusta.edu
- CO-338-043: ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Clinical Trial
CO-338-043: ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The purpose of this study is to compare the safety and into-tumor effect of rucaparib with that of chemotherapy in patients whose tumors did not respond or stopped responding to treatment. One of the main goals of the biomarker research is to develop a diagnostic test that might help show which patients are most liekly to benefit from treatment with rucaparib.
Eligibility Criteria
- Subjects must be at least 18 years of age or older. They must have histologically confirmed diagnosis of high-grade serous or Grade 2 or Grade 3 endometriod epithelial ovarian, fallopian tube, or primary peritoneal cancer. Must have received a least 2 or more prior chemotherapy regimens and have relapsed or progression diease confirmed by radiologic assessment.
RESEARCH. INNOVATION. DISCOVERY.